FDA moves toward easing restrictions on certain peptides BioPharma Dive The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Best BPC 157 Oral Supplements: ProHealth's Triple Tested Formula Examined as Peptide Quality Verification Becomes Consumer Priority Heading Into 2026 FDA Issues Warning Letters Against Online GLP 1 Sellers BioSpace Sources: U.S. Food and Drug Administration (FDA) Compounding and the FDA (503A & 503B guidance) FDA warning letters on unapproved peptide products National Institutes of Health (NIH) PubMed